Regeneron pays $100M milestone to Alnylam; NIH awards Clene $45M; Biohaven raises $258M
Regeneron pays out $100M proof-of-principle milestone: Regeneron said Thursday it will take a $100 million charge in the third quarter after paying out a development milestone to Alnylam for their ALN-APP program in early-onset Alzheimer’s disease. Back in April, the companies shared preliminary data from a Phase I study that showed the therapy reduced levels of proteins tied to Alzheimer’s. They first struck a deal in 2019. — Jaimy Lee
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
